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ABSTRACT The addition offresh medium supplemented with
partially purified platelet-derived growth factor (PDGF) to quies-
cent density-arrested cultures ofBALB/c-3T3 cells decreases the
subsequent binding of radiolabeled epidermal growth factor
(EGF). The decrease in EGF binding can be observed 1 hr after
the addition ofPDGF. This effect is maximal in 2-3 hr, and bind-
ing remains diminished for at least 6 hr. These effects can be ac-
counted for by a decrease in the number of EGF receptors with
no change in receptor affinity. The action ofPDGF is concentra-
tion dependent, but even at very high concentrations ofPDGF the
reduction in EGF binding is never more than 50%. Similar de-
creases in EGF binding are produced by other treatments that
render BALB/c-3T3 cells competent, such as the addition of fi-
broblast growth factor or medium previously exposed to the mac-
rophage-like cell line P388D1. Cholera toxin (choleragen), which
alone had no effect on EGF binding, dramatically potentiated the
ability of PDGF to down regulate EGF receptors. Two to three
hours after the addition of PDGF and choleragen, EGF binding
was reduced by 80-90% compared with control values. The ability
of PDGF and choleragen together to decrease EGF binding was
substantially inhibited by cycloheximide. Autoradiography of
[3HJthymidine-labeled cells shows that choleragen potentiates the
action of PDGF; lower concentrations of PDGF are required to
make cells competent after choleragen treatment. Furthermore,
cells treated with PDGF and choleragen no longer require EGF
for traverse ofG1 phase and initiation ofDNA synthesis in defined
medium. The reduction in receptor number produced by chol-
eragen and PDGF, which may be due to internalization of the
EGF receptor, may mimic the action ofEGF and thereby remove
the EGF requirement for DNA synthesis.
The serum-derived factors that control Go/G1 traverse in den-
sity-arrested BALB/c-3T3 cells can be divided into two func-
tionally distinct components (1). Platelet-derived growth factor
(PDGF) acts initially to render cells competent to respond to
serum-derived factors (progression factors) that are also present
in platelet-poor plasma (1, 2). Competent PDGF-treated cells
traverse GO/GI and initiate DNA synthesis a minimum of 12
hr after the addition of medium supplemented with plasma (1,
2). Furthermore, a combination of epidermal growth factor
(EGF) and somatomedin C in defined medium is as effective
as plasma-supplemented medium in promoting the progression
of competent BALB/c-3T3 cells (3).
The biochemical mechanisms by which PDGF renders cells
sensitive to EGF and somatomedin C are ofgreat interest. Pep-
tide factors might act in concerted fashion if one were able to
modulate either the number or affinity of the receptors for an-
other peptide. Clemmons and Van Wyk (4) reported that PDGF
caused no change in somatomedin C binding, although treat-
ment of competent cells with plasma-supplemented medium
doubled the number of somatomedin C receptors. Wrann et al.
(5) reported that, in serum-starved Swiss 3T3 cells, PDGF
caused a transient down regulation ofEGF receptors, and Hel-
din et al. (6) recently confirmed this observation. Here, we re-
port that, in density-arrested BALB/c-3T3 cells, PDGF caused
a persistent decrease in EGF binding that appeared to be due
to loss ofEGF receptors. PDGF-induced loss of EGF binding
was markedly enhanced by choleragen, which has been re-
ported to increase the mitogenic action of PDGF (7). Enhanced
loss of EGF receptors after treatment with PDGF and chol-
eragen was coincidental with an abrogation ofthe EGF require-
ment for progression to S phase of the cell cycle.
MATERIALS AND METHODS
Cell Culture. BALB/c-3T3 cells (clone A31) were grown in
Dulbecco-Vogt modified Eagle's (DME) medium/10% heat-
inactivated calf serum/4 mM glutamine, supplemented with
penicillin at 50 units/ml and streptomycin at 50 ,g/ml in hu-
midified 5% C02/95% air at 37°C.
Binding Studies. To prepare cells for binding studies, ap-
proximately 3 x 10' cells suspended in 2 ml of serum-supple-
mented DME medium were plated in 35-mm culture dishes.
The medium was changed after 3 days and the cells were used
5 to 6 days later. After treatment at 370C with DME medium
containing 0.25% platelet-poor plasma (DME-LP medium),
cultures were placed on ice and washed with Hanks' buffered
salt solution containing 30 mM Hepes, pH 7.4/0.1% bovine
serum albumin (medium A) at 4°C. Plates were then incubated
for 4 hr at 40C in 0.5 ml of medium A containing '251-labeled
EGF. Nonspecific binding was determined in the presence of
native EGF at 1 ,ug/ml. At the end of the incubation period,
cultures were washed three times with 2 ml of cold medium A,
and bound 125I-labeled EGF was solubilized in 0.1 M NaOH/
1% NaDodSO4 and assayed in a gamma counter. Only specific
binding is shown in the figures and tables. All studies were re-
peated at least three times with similar results. Binding equi-
librium is at least 95% complete at 3 hr.
DNA Synthesis Assay. Cells were grown to confluence in 96-
well microtiter plates containing serum-supplemented DME
medium at 0.2 ml per well. Two to three days after the cells
reached density-dependent growth arrest, the medium was
changed to DME medium containing [3H]thymidine at 5 ,tCi/
Abbreviations: DME medium, Dulbecco-Vogt modified Eagle's me-
dium; DME-LP medium, DME medium containing 0.25% platelet-
poor plasma; PDGF, platelet-derived growth factor; EGF, epidermal
growth factor; FGF, fibroblast growth factor.
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ml (6.7 Ci/mmol; 1 Ci = 3.7 X 1010 becquerels) and various
supplements. At the end of the experiment, cells were fixed
with methanol and processed for autoradiography as described
(1).
Preparation of Growth Factors. Partially purified PDGF
was prepared from boiled extracts of outdated human platelets
as described by Antoniades and Scher (8). Preparations of
PDGF were chromatographed on CM-Sephadex and then in
1 M acetic acid on Bio-Gel P-150. Active fractions were col-
lected, pooled, and lyophilized. Platelet-poor plasma was pre-
pared as described by Pledger et al (1) from peripheral venous
blood drawn from healthy volunteers. EGF was purified from
mouse submaxillary glands by the procedure of Savage and
Cohen (9) and was labeled with Na'15I to a specific activity of
1.2 Ci/pumol by the method of Hunter and Greenwood (10) as
described (11). Fibroblast growth factor was a gift from D. Gos-
podarowicz. Bovine insulin was purchased from Sigma.
Materials. DME medium was purchased from Flow Labo-
ratories. Antibiotics were from GIBCO, and serum was from
Colorado Serum Company (Denver, CO). Microtiter plates
were from Nunc (GIBCO). Other plastic culture ware was from
Fisher Scientific, and chemicals were purchased from Sigma.
RESULTS
PDGF-Induced Decrease in EGF Binding. Addition of
DME-LP medium supplemented with partially purified PDGF
to quiescent density-arrested cultures of BALB/c-3T3 cells rap-
idly decreased the ability of the cells to bind "2I-labeled EGF
(Fig. 1A). When DME-LP medium alone was added to quies-
cent cultures, there was no change in "2I-labeled EGF binding
over a 4-hr period. When medium containing partially purified
PDGF at 2.5 ug/ml was added, however, binding of 15I-la-
beled EGF decreased 25% within 1 hr and to 45% of control
levels within 3 hr. Between 3 and 5 hr after addition ofPDGF,
there was no further reduction in binding. These results are
similar to those observed after addition ofEGF to cultured cells.
In what has been termed down regulation, EGF induces a spe-
cific decrease in the number ofEGF membrane receptors (12,
13). The effects of our partially purified PDGF preparations
cannot be attributed to contamination by EGF because, both
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FIG. 1. 1251-Labeled EGF binding after addition of PDGF. (A)
Quiescent cultures of BALB/c-3T3 cells were treated at 0 hr with
medium containing 0.25% platelet-poor plasma (d) or with medium
containing 0.25% plasma and partially purified PDGF at 2.5 ug/ml
(o). At the indicated times, medium was changed and '25I-labeled EGF
binding of triplicate cultures was measured. (B) *-* and o-k--o,
cultures were treated as inA, except that partially purified PDGF was
used at 5.0 pLg/ml; *---_ and o---o, cultures also received choler-
agen at 1 /g/ml. Only specific binding is shown.
by radioreceptor assay and by radioimmunoassay, the undiluted
PDGF did not contain detectable (0.1 ng/ml) amounts ofEGF
(data not shown). This effect was also not due to a general de-
crease in membrane hormone receptors, because the prepa-
ration of PDGF used in these experiments did not alter so-
matomedin C binding (data not shown), in agreement with the
results of Clemmons and Van Wyk (4).
Potentiation of PDGF Action by Choleragen. We have pre-
viously found that choleragen, a potent activator of adenylate
cyclase in cultured cells (14), potentiates the ability of PDGF
to render cells competent (7). Choleragen also potentiated the
ability of PDGF to reduce '25I-labeled EGF binding to BALB/
c-3T3 cells (Fig. 1B). Addition ofeither DME-LP medium alone
or DME-LP medium containing choleragen at 1 ,g/ml to
quiescent cells did not change " I-labeled EGF binding. Ad-
dition ofDME-LP supplemented with partially purified PDGF
at 5 pug/ml caused a 50% reduction in EGF binding within 2
hr, similar to the results shown in Fig. 1A; addition of medium
containing both PDGF and choleragen, however, produced a
much more dramatic decrease in EGF binding. By 1 hr after
addition, EGF binding was decreased by 40%, and by 4 hr, the
combination of PDGF and choleragen had almost abolished the
ability of the cells to bind "2I-labeled EGF.
As shown in Fig. 2, the effect ofPDGF on EGF binding was
concentration dependent in both the presence and the absence
ofcholeragen. When medium supplemented with PDGF alone
was added to quiescent BALB/c-3T3 cells for 4 hr, there was
a concentration-dependent decrease in 1"I-labeled EGF bind-
ing. A maximum reduction in binding ofapproximately 50% was
observed at PDGF concentrations of either 0.75 or 1.0 pug/ml
when PDGF purified on Bio-Gel P-150 was used. In experi-
ments not shown, the PDGF concentration was increased to 10
,ug/ml with no further decrease in binding over that shown in
Fig. 2. In the presence of choleragen at 1.0 ug/ml, PDGF
caused a much greater reduction in "I-labeled EGF binding.
At 0.25 jug/ml, PDGF reduced EGF binding by more than
40% and, at 1 jg/ml, PDGF reduced EGF binding by approx-
imately 90%. In the presence ofcholeragen, therefore, not only
did PDGF decrease "2I-labeled EGF binding at lower con-
centrations, but the magnitude ofthe decrease was greater than
that observed with PDGF alone, even when very high concen-














FIG. 2. Concentration-dependent effects of PDGF. At 0 hr, quies-
cent cultures of BALB/c-3T3 cells were treated with medium contain-
ing Bio-Gel-purifiedPDGF either alone (e) or with choleragen at 1 Ag/
ml (0). After a 4-hr incubation of 370C, medium was changed and'25I-labeled EGF binding was determined.
Proc. Nad Acad. Sci. USA 79 (1982)
Proc. Natl. Acad. Sci. USA 79 (1982) 5569
regulation of EGF receptors by EGF (data not shown).
There is a lag following the addition of choleragen before
maximal effects on adenylate cyclase are observed (14). As
shown in Fig. 3, if BALB/c-3T3 cells are treated with choler-
agen for 2 hr prior to the addition of PDGF, the decrease in
EGF binding occurs more rapidly. Addition ofeither DME-LP
medium alone or DME-LP medium containing PDGF at 1 ,ug/
ml caused effects on EGF binding similar to those shown above
(data not shown). If PDGF and choleragen were added to-
gether, the decrease in binding observed 1 hr later was similar
to that seen after the addition of PDGF alone, but at 2 hr the
binding of "NI-labeled EGF was decreased by 70%. When the
cells were treated for 2 hr with choleragen before the addition
of PDGF, EGF binding was decreased almost 70% 1 hr after
the addition of PDGF. At 2 hr, the decrease in binding in cells
previously treated with choleragen was similar to the maximum
decrease in binding measured in cultures treated with PDGF
and choleragen together. Biologically inactive choleragenoid
did not affect PDGF-mediated down regulation ofEGF recep-
tors, but the action of PDGF was potentiated by 8-bromo-
cAMP or isobutylmethylxanthine (data not shown).
EGF Binding After Treatment With Other Competence
Factors. Fibroblast growth factor (FGF), which has been shown
to render cells competent in a manner similar to that ofPDGF
(15), also decreased EGF binding. Addition ofmedium supple-
mented with FGF at 100 ng/ml reduced EGF binding by ap-
proximately 35% compared with cultures treated with unsup-
plemented DME-LP medium. Addition of medium containing
choleragen alone caused little change in EGF binding. How-
ever, when choleragen and FGF-supplemented medium were
added together, a potentiation of the decrease in EGF binding
similar to that described above for PDGF occurred. We have
previously reported that choleragen potentiates the ability of
FGF to render cells competent (7).
The macrophage-like cell line P388D, expresses a mitogenic
activity that renders BALB/c-3T3 cells competent to respond
to plasma (16). P388D1-conditioned medium decreased EGF
binding to an extent similar to that observed after treatment
with PDGF or FGF (data not shown).
Decrease in EGF Binding Is Due to Loss of Receptors. The
effects shown in Figs. 1-3 could have been due to a decrease













FIG. 3. Effect of prior treatment with choleragen. Quiescent cul-
tures of BALB/c-3T3 cells were treated at 0 hr with medium contain-
ing 0.25% platelet-poor plasma alone (o e), PDGF at 10 ,g/ml
(.---.), or platelet-poor plasma, PDGF, and choleragen at 1 ,ug/ml
(o-o). Another culture was treated with platelet-poor plasma,
PDGF, and choleragen at 2 hr (o---o). 125I-Labeled EGF binding was
determined in triplicate cultures.
Table 1. Binding of '251-labeled EGF to 3T3 cells after treatment
with FGF
125I-Labeled EGF bound,
Treatment cpm per plate
DME medium 30,216
FGF (100 ng/ml) 19,794
Choleragen (1 ,.tg/ml) 31,915
FGF/choleragen 3,363
Quiescent cultures of BALB/c-3T3 cells were washed and incubated
for 4 hr at 370C in DME-LP medium supplemented with various com-
binations of FGF and choleragen. At the end of treatment, the cultures
were washed and the amount of 1251-labeled EGF binding was deter-
mined. Results are means of duplicate samples (corrected for nonspe-
cific binding). Duplicate values did not vary by more than 2% from
means.
of the receptors for "25I-labeled EGF, or some combination of
both effects. To distinguish between these alternatives, sets of
quiescent cultures were incubated for 4 hr in DME-LP medium
alone or DME-LP medium containing partially purified PDGF
at 1 Ag/ml. The cells were then washed and incubated at 40C
with various amounts of '25I-labeled EGF (0. 061-1. 0 x 106 cpm
per plate; 0.1-1.7 nM). The amounts of '25I-labeled EGF spe-
cifically bound at the end of a 4-hr incubation are shown in Fig.
4A. The amount of bound EGF at each concentration of the
peptide was less in the PDGF-treated cultures, although bind-
ing saturated in both cases at approximately the same concen-
tration of EGF. Scatchard analysis (17) ofthe data shown in Fig.
4A showed that the decrease in binding was due to a decrease
in the number of EGF receptors (from 5.0 X 104 sites per cell
to 2.7 x 104 sites per cell) with no change in affinity (Kd = 0.5
nM).
Effects of Cycloheximide on PDGF-Induced Down Regu-
lation of EGF Receptors. The ability of EGF to modulate the
number ofEGF receptors on target cells occurs in the presence
ofcycloheximide (13). Incubation ofcells in cycloheximide alone
produces a slow decrease in EGF binding in cells not exposed
to EGF. In contrast, the reduction in EGF binding produced
by PDGF alone or by PDGF and choleragen together was
strictly dependent on continued protein synthesis (Table 2). In
the absence ofcycloheximide, PDGF reduced EGF binding by
approximately 30% after 4 hr, while a combination of PDGF
and choleragen reduced binding by more than 80%. When cells
were incubated in DME-LP medium containing only cyclo-
heximide, binding was decreased approximately 15% compared
with control cultures. Cycloheximide and PDGF together did
not cause a decrease in binding over that observed with cyclo-
heximide alone, and the combination ofPDGF and choleragen
reduced the amount of EGF bound by only about 10%. Thus,
in contrast to the loss of EGF binding observed after exposure
to EGF, the PDGF-induced reduction in EGF binding was less
when protein synthesis was inhibited.
Choleragen Abrogated the Requirement for EGF. Re-
cently, serum-free medium supplemented with PDGF, EGF,
and either somatomedin C or supraphysiological concentrations
of insulin was shown to initiate DNA synthesis in quiescent
density-arrested cultures ofBALB/c-3T3 cells (3). As shown in
Table 3, incubation in medium containing PDGF, EGF, and
insulin stimulated 75% of the cells to undergo DNA synthesis.
PDGF together with insulin or EGF allowed 19% and 10% of
the cells, respectively, to enter S phase.
In the presence of choleragen, PDGF and insulin together
allowed 77% of the cells to initiate DNA synthesis. PDGF and
EGF together (without insulin or somatomedin C) did not stim-
ulate cells to enter S phase, even in the presence of choleragen.
Therefore, choleragen abrogated the requirement for EGF, but
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FIG. 4. Saturation of '25I-labeled EGF binding with and without
PDGF treatment. Quiescent cultures of BALB/c-3T3 cells were in-
cubated for 4hrwithDME-LP medium with (.) orwithout (0) partially
purified PDGF at 10 pug/ml. Medium was changed and binding was
assessed in triplicate cultures. (A) Binding curve. (B) Scatchard plot
of the binding data.
not for insulin, in defined medium. Stimulation in medium con-
taining PDGF, insulin, and EGF together or PDGF, insulin,
and choleragen together was equal to stimulation in medium
containing PDGF and plasma. Purified FGF and, insulin to-
gether in the presence of choleragen also abrogated the re-
quirement for EGF (data not shown).
DISCUSSION
In quiescent density-arrested BALB/c-3T3 cells, several serum
factors act sequentially to control traverse of the Go/Gj phase
and progression to DNA synthesis. Putative regulatory events
Table 2. Effect of cycloheximide on reduction in EGF binding
by PDGF




PDGF (1 jug/ml) 25,945 34,219
Choleragen (1 Sgml) 40,016 31,766
PDGF/choleragen 7,198 28,615
Quiescent density-arrested cultures of BALB/c-3T3 cells were
treated with PDGF or choleragen for 4 hr in the presence or absence
of cycloheximide at 5 /g/ml. The cells were then washed, '25I-labeled
EGF (400,000 cpm per plate) was added, and mixtures were incubated
for 4 hr at 40C. Results are means of duplicate plates corrected for non-
specific binding measured in the presence of unlabeled EGF at 1 pg/
ml.








Quiescent BALB/c-3T3 cells were incubated for 36 hr in DME me-
dium supplemented with the indicated combinations of partially pu-
rified PDGF (3.1 W'ml), EGF (10 ng/ml), and insulin (10 pM) in the
presence or absence of choleragen at 1 ,ug/ml. All culture media also
contained [5H]thymidine at 5 gCi/ml. At the end of the incubation
period, the cells were fixed with methanol and processed for autora-
diography, and the percentage of cells incorporating [5Hlthymidine
was determined. The PDGF concentration in these experiments in-
duced 82% of the cells to undergo DNA synthesis in the presence of
5% platelet-poor plasma. At this high concentration of PDGF, addition
of choleragen had little effect' when the cells were incubated in 5%
plasma-containing medium. Similar results were obtained in four
experiments.
can be studied rigorously through the use of purified growth
factors. PDGF apparently acts initially in the cell cycle to render
cells competent to respond either to the progression factors in
platelet-poor plasma (1, 2) or to purified EGF together with
somatomedin C (or insulin at higher concentrations) (3). The
biochemical mechanisms by which PDGF allows cells to re-
spond to EGF or insulin-like growth factors are important
growth-controlling events. Pledger et aL (18) have shown that
specific cellular proteins are preferentially synthesized when
BALB/c-3T3 cells. are exposed to competence factors. Both
PDGF and FGF induce competence formation and down reg-
ulate receptors for EGF, a progression factor. The importance
in the mitogenic response of down regulation of receptors by
the same factor (homologous down regulation) or by another
factor (heterologous down regulation) is unknown. Transient
down regulation of EGF receptors by PDGF has been de-
scribed (5). We have demonstrated a more persistent effect by
PDGF and FGF that is concentration dependent and, like
EGF-induced down regulation, is associated with loss of bind-
ing sites with no change in affinity (Figs. 2 and 4).
Choleragen has been reported to stimulate proliferative
growth in epidermal cells (19), endothelial cells (20), and mouse
fibroblasts (7, 21, 22). Through study of sequential events using
PDGF and plasma, we recently demonstrated that the stimu-
latory action of choleragen and other agents elevating intracel-
lular cAMP is on the early events associated with competence
formation, since choleragen reduces the concentration of
PDGF required for maximal (greater than 90%) stimulation of
DNA synthesis in quiescent BALB/c-3T3 cells; i.e., it poten-
tiates competence factors but is inactive alone or when added
after competence formation during progression (7). This poten-
tiation appears to be cAMP mediated, since it is, also found to
occur with 8-bromo-cAMP, is enhanced by isobutylmethylxan-
thine, and does not occur with choleragenoid (data not shown).
We have found that choleragen, which by itselfhas no effect
on binding of "2I-labeled EGF, potentiates the ability of the
competence factors, PDGF and FGF, to down regulate EGF
receptors. It is only this heterologous down regulation that is
affected by choleragen; EGF-induced down regulation ofEGF
receptors is not affected (data not shown). Heterologous down
regulation differs from that induced by EGF in another im-
portant respect. It is sensitive to cycloheximide, but EGF-in-
duced down regulation ofEGF receptors in BALB/c-3T31 cells
is not (13). The potentiation of the PDGF-induced down reg-
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ulation of EGF receptors by choleragen is also cycloheximide
sensitive, suggesting that choleragen may affect the same pro-
cess that is controlled by PDGF. Potentiation of heterologous
down regulation by choleragen appears to be mediated by
cAMP. It does not occur with choleragenoid, is also produced
by 8-bromo-cAMP, and is potentiated by isobutylmethylxan-
thine (data not shown). Cells treated with PDGF with or with-
out choleragen apparently do not produce EGF or a substance
interacting with the EGF receptor; conditioned medium from
treated cells is inactive in the radioreceptor assay, which is sen-
sitive to EGF at 0.1 ng/ml (data not shown). The down regu-
lation therefore appears to be truly heterologous.
That alterations in surface receptors may have significance
for growth is suggested by several findings. Antireceptor anti-
bodies to the insulin receptor (23), to the EGF receptor (24),
and to the catecholamine receptor (25) have been shown to sim-
ulate the action of the natural ligand. Antibody to the EGF re-
ceptor is mitogenic (24), indicating that EGF is not required,
not only for short-term effects such as phosphorylation, but also
for the long-term effect DNA synthesis. Similar results were
found when antibodies to EGF, used presumably to crosslink
a nonmitogenic derivative of EGF (cyanogen bromide-treated
EGF), rendered the derivative capable of initiating DNA syn-
thesis (26). These findings suggest that crosslinking ofreceptors
followed by clustering and internalization may be significant
effects of the natural ligands with respect to biologic action.
In both PDGF-treated cells and cells treated with choleragen
and PDGF together, the readiness ofthe cell to begin cell cycle
traverse is associated with a decrease in EGF binding. Viral
transformation is associated with both a decrease in EGF bind-
ing (27) and loss ofthe requirement for competence factors (15).
During liver regeneration in rats, a dramatic decrease in EGF
binding occurs (28). A prompt decrease in EGF receptors oc-
curring in diverse settings associated with proliferative growth
suggests that this may be part of an overall growth response by
the cell. The demonstration in the present study that down reg-
ulation ofEGF receptors by PDGF and choleragen permits fi-
broblasts to proceed to synthesize DNA in the absence ofEGF,
for which there is ordinarily an absolute requirement in defined
medium, is also compatible with this general argument.
Whether heterologous down regulation is accompanied by clus-
tering and internalization of EGF receptors has not been de-
termined; if so, the present results suggest that these actions
of the receptor, whether induced by PDGF together with chol-
eragen, anti-EGF receptor antibody, or EGF, may be required
for mitogenesis. Anti-EGF antibody can effectively prevent the
mitogenic action of EGF in human fibroblasts for up to 8 hr
(12, 26). Because down regulation ofEGF receptors is maximal
within 3 to 4 hi, modulation of surface receptors alone does not
appear to be sufficient for mitogenesis. Nevertheless, down
regulation of certain receptors may be necessary before pro-
gression can occur.
The ability of agents elevating cAMP concentrations to mod-
ulate receptor topography was recently demonstrated for thy-
rotropin receptors, which cluster in response to cAMP analogs
(29). This was suggested to imply feedback regulation of recep-
tor topology by the cAMP messenger of thyrotropin action.
Potentiation of mitogenesis and of heterologous down regula-
tion of EGF receptors by choleragen suggests that alterations
in cAMP may have more general implications for receptor dy-
namics, since cAMP does not appear to be involved directly in
the action of EGF.
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